<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706835</url>
  </required_header>
  <id_info>
    <org_study_id>ALDOXORUBICIN-P1-PK-01</org_study_id>
    <nct_id>NCT01706835</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 open-label study to investigate the pharmacokinetics of aldoxorubicin
      administered as a 30 minute infustion every 3 weeks for up to 8 cycles in subjects with
      advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label Phase 1 Study to Investigate the Pharmacokinetics of Aldoxorubicin Administered
      as a 30 Minute Infusion Every 3 Weeks in Subjects with Advanced Solid Tumors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Blood samples will be obtained for pharmacokinetics. Standard pharmacokinetic parameters, including t1/2, Cmax, AUC, Vd and CL, will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 6 months</time_frame>
    <description>All subjects who receive any amount of aldoxorubicin will be included in the safety analyses, which will include the following:
The incidence, severity, duration, causality, seriousness, and type of AEs and changes in the subject's physical examination, vital signs, and clinical laboratory results.
Deaths and other SAEs will be tabulated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Aldoxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aldoxorubicin</intervention_name>
    <arm_group_label>Aldoxorubicin</arm_group_label>
    <other_name>INNO-206</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥18 years, male or female.

          2. Histologically or cytologically confirmed malignant solid tumor that has relapsed or
             is refractory to standard therapy.

          3. Subjects who have received prior radiation therapy with stable central nervous system
             (CNS) metastasis with no progression of brain metastasis by CT/MRI scan in last 4
             weeks.

          4. Capable of providing informed consent and complying with trial procedures.

          5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.

          6. Life expectancy &gt;12 weeks.

          7. Measurable or evaluable disease.

          8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,
             surgically sterile, or practicing adequate birth control methods) for the duration of
             the study. [Adequate contraception includes: oral contraception, implanted
             contraception, intrauterine device implanted for at least 3 months, or barrier method
             in conjunction with spermicide.].

          9. Women of child bearing potential must have a negative serum or urine pregnancy test at
             the Screening Visit and be non-lactating.

         10. Geographic accessibility to the site.

        Exclusion Criteria:

          1. Palliative surgery, chemotherapy, immunotherapy and/or radiation treatment less than 4
             weeks prior to the Screening Visit.

          2. Exposure to any investigational agent within 30 days of the Screening Visit.

          3. Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL,
             alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or
             5 times the ULN in liver metastases, total bilirubin greater than 3 times the ULN,
             white blood cell (WBC) count &lt;3500/mm3, absolute neutrophil (ANC) count &lt; 2000/mm3,
             platelet concentration &lt;100,000/mm3, hematocrit level &lt;25% for females or &lt;28% for
             males (transfusion is allowed during screening).

          4. Clinically evident congestive heart failure (CHF) &gt; class II of the New York Heart
             Association (NYHA) guidelines.

          5. Serious, clinically significant cardiac arrhythmias, defined as the existence of an
             absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.

          6. Recent history (within 6 months) or current signs of active coronary artery disease
             with or without angina pectoris.

          7. Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram)
             or ultrasound determined absolute left ventricular ejection fraction (LVEF) &lt;45% of
             predicted.

          8. Known history of HIV infection.

          9. Active, clinically significant serious infection requiring treatment with antibiotics,
             antivirals or antifungals.

         10. Major surgery within 4 weeks prior to treatment.

         11. Substance abuse or any condition that might interfere with the subject's participation
             in the study or in the evaluation of the study results.

         12. Any condition that is unstable and could jeopardize the subject's participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Levitt, MD</last_name>
    <role>Study Director</role>
    <affiliation>CytRx Coorporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>aldoxorubicin</keyword>
  <keyword>phase 1</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>INNO-206</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

